HealthArs Technicaabout 6 hours ago
Trump linked to experimental obesity drug case
1 min read
A single 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide through the FDA's compassionate use program. Stat News reported the patient may be President Donald Trump. The drug targets GIP, glucagon, and GLP-1 hormones. A Phase 3 trial showed 28 percent weight loss over 80 weeks.
Level
Hype check
Tap to vote and see what everyone thinks.
